Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating whether regular radiological assessments during follow-up after surgery for high-risk malignant melanoma improve patient survival. The study addresses concerns about the resource demands, potential radiation exposure, and anxiety caused by such imaging, especially given the recent introduction of effective medical treatments for melanoma. There is currently no clear evidence supporting routine imaging in this context. Participants are randomly assigned to one of two groups. One group follows national guidelines with regular doctor appointments for 3 years, while the other group receives the same follow-up plus additional whole-body CT or PET scans and blood tests at baseline, 6, 12, 24, and 36 months. An interim analysis will be done after 1,000 patients enroll. During the study, researchers will monitor overall survival at 5 years as the primary outcome. They will also assess quality of life through questionnaires over the 3-year follow-up. Participants will attend scheduled visits for clinical evaluations, imaging, and blood tests, with the study aiming to provide clear evidence about the role of imaging in post-surgical melanoma care.
Actively Recruiting
Researchers are evaluating whether a shorter period of immunotherapy after radical surgery is as effective as the standard longer treatment for patients with high-risk malignant skin melanoma. This study focuses on people aged 18 and older who have undergone surgery for stage IIb-c, III, or IV melanoma. The goal is to see if six months of immunotherapy can prevent cancer recurrence as well as the current 12-month treatment, potentially reducing side effects, hospital visits, and healthcare costs. The study is a randomized phase 3 trial conducted internationally with patients followed for up to five years. Participants will receive immunotherapy drugs, currently nivolumab or pembrolizumab, given intravenously. They are randomly assigned to either six months experimental group or 12 months standard group of treatment. Patients who had immunotherapy before surgery neoadjuvant treatment can also join, with their pre-surgery treatment time added to the post-surgery treatment. Medical exams and imaging scans CT or PET-CT are done at the start, six months, and 36 months, along with regular check-ups over three years. If cancer returns, additional tests and treatments are planned based on medical team decisions. During the study, participants will have scheduled visits for physical exams, blood tests, and scans to monitor their health and detect any recurrence. Researchers will measure relapse-free survival and distant metastatic-free survival at two years as primary outcomes, with overall survival and health economic effects also assessed over five years. Safety monitoring includes standard care practices and follow-up for up to five years. The study aims to confirm if shorter immunotherapy duration maintains the same outcomes while benefiting patients and healthcare systems.
Actively Recruiting
Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.
Actively Recruiting
This research aims to explore the risk of early postoperative nausea and vomiting PONV at the recovery unit after surgery by analyzing data collected in the Swedish Perioperative Registry SPOR from 2016 to 2022. The study focuses on adult patients who underwent surgical procedures under general or regional anesthesia and were admitted to a recovery unit for initial postoperative care. The goal is to identify factors associated with early PONV across various surgical cohorts on a national scale. The study uses registry data reported by nearly all hospitals in Sweden, which includes almost 1.7 million procedures for patients aged 18 and older between 2016 and 2019. Hospitals may choose to record PONV occurrences at the recovery unit, categorizing patients as having no nausea or vomiting, nausea only, or nausea and vomiting. Data extraction and analysis are planned yearly until 2029, allowing for ongoing updates from the registry to report on selected cohorts and surgical types. Participants are not actively treated but are observed through existing registry data. Researchers assess the presence of PONV within 24 hours after surgery at the recovery unit. The study involves continuous data collection through SPOR with yearly updates and reports. This approach enables the team to evaluate the risk and associated factors of early PONV in a large, real-world surgical population over several years.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Spontaneous intracerebral hemorrhage ICH is a serious type of stroke with high death and disability rates. Researchers are investigating whether a structured treatment package called a Care Bundle can improve the 3-month outcomes for patients with acute ICH compared to standard care. The study is an international, multicenter, parallel, cluster-randomized clinical trial focusing on implementing this Care Bundle in high-income countries, building on results from previous trials mostly done in low- and middle-income countries. The Care Bundle includes early intensive blood pressure lowering, treatment of fever and high blood sugar, rapid reversal of oral anticoagulation, and timely referrals to intensive care or neurosurgery when needed. Hospitals are randomized in batches through three phases usual care, randomized evaluation of the Care Bundle versus usual care, and a post-implementation follow-up where all hospitals apply the Care Bundle. Each batch lasts 18 months, with 6 months per phase, and the overall study rollout spans 2.5 years. Participants are adults aged 18 or older diagnosed with spontaneous ICH confirmed by imaging within 24 hours of symptom onset. During the study, patient management details and outcomes will be closely monitored, including brain imaging, blood pressure, glucose levels, and functional status. The primary outcome is functional recovery measured by a utility-weighted modified Rankin Scale score at 180 days. Secondary outcomes include disability, death, and health-related quality of life. The study also collects data on treatments and care decisions to evaluate the Care Bundles effectiveness and sustainability.
Actively Recruiting
Researchers are evaluating a new e-health program designed to improve the neurodevelopment of very preterm infants, born before 32 weeks or with low birth weight, by supporting parents in responsive caregiving. The study aims to see if this program, called INSPIRE, can enhance cognitive, motor, feeding, language, and socio-emotional development up to 2 years of age. Additional goals include assessing parental stress, emotional availability, health inequalities, and gender differences. This trial is conducted by Ume University with a multi-professional team and builds on a pilot study involving nine families. The intervention group will receive the INSPIRE program, which consists of 18 sessions delivered digitally over two years, starting at hospital discharge. This program focuses on strengthening parent-child interactions and empowering parents with responsive parenting skills. Families in the control group will receive standard care without the INSPIRE intervention. The study randomly assigns families to either group and follows up with assessments over time. Participants will be involved from discharge through at least 2 years corrected age, with evaluations including neurodevelopmental tests such as the Bayley Scales of Infant Development at 24 months. Additional assessments cover motor skills, language, feeding, emotional availability, parental stress, and mental health using various standardized tools at multiple time points up to 5.5 years of age. Researchers will monitor child development, parent well-being, and other outcomes to understand the interventions impact and safety over the study period.
Actively Recruiting
Researchers are evaluating a treatment approach for patients with newly diagnosed glioblastoma that have a methylated MGMT promoter, a specific genetic feature of the tumor. This phase 3 clinical trial compares the standard chemotherapy drug Temozolomide TMZ alone to a combination of Temozolomide plus Lomustine LOM. The study aims to determine if adding Lomustine improves survival rates, progression-free survival, safety, quality of life, and cognitive function. Participants are randomly assigned to one of two groups. The control group receives Temozolomide during and after radiation therapy. The experimental group receives both Temozolomide and Lomustine starting on the first day of radiation. Lomustine and Temozolomide are given as oral pills in cycles, with Lomustine cycles lasting 42 days for a total of six cycles over about nine months, while Temozolomide cycles last 28 days with six cycles over about 8.5 months. Radiation therapy is given concurrently with the start of chemotherapy in both groups. During the study, participants will have regular assessments including survival monitoring, tumor progression checks, and safety evaluations for side effects. Quality of life and detailed neurocognitive tests measuring memory, attention, motor skills, and reaction times are conducted at the start, end of radiotherapy, and every 24 weeks for up to 36 months. Adverse events are tracked from randomization until death or three years of follow-up. The study involves close monitoring to understand the long-term effects and benefits of adding Lomustine to standard treatment.
Actively Recruiting
Researchers are evaluating data from Swedish national registries to study the occurrence of pain and postoperative nausea and vomiting PONV after gallbladder surgery. The study aims to understand factors linked to higher risks of PONV and pain, including patient characteristics and surgical details. It also explores whether different anesthesia types and regional blocks affect these outcomes and the risk of complications up to six months after surgery. This observational study uses linked data from the Gallriks registry for gallbladder surgeries and the Swedish Perioperative Register SPOR, which records detailed perioperative and postoperative information. Data include patient health, surgery details, anesthesia, pain scores, nausea, and complications. The study includes patients who had gallbladder surgery between 2016 and 2025, with data updated yearly. The study database will analyze thousands of cases, focusing on early postoperative pain and nausea during the average 3.5-hour stay in the post-anesthesia care unit PACU. Participants involvement is through the collection and analysis of registry data with no direct interventions. Researchers will assess pain scores, nausea occurrence, and complications up to six months post-surgery. The study uses descriptive and statistical analyses to identify associations between patient or surgical factors and outcomes. Personal data are pseudonymized to protect privacy. The study period covers surgeries over ten years, allowing comprehensive long-term evaluation.
Actively Recruiting
Researchers are investigating whether adding physical exercise during neoadjuvant chemotherapy NACT can improve outcomes for patients with primary invasive breast cancer. This trial focuses on whether exercise can increase the rate of pathological complete response pCR, meaning no invasive tumor remains after chemotherapy. Secondary goals include evaluating cancer burden after treatment, tumor response through imaging, quality of life, physical activity levels, muscle strength, fitness, cognitive effects, treatment completion, and long-term sick leave. The study also explores how exercise may influence anti-tumor mechanisms. Participants will be randomly assigned to one of two groups usual care with routine information about physical activity or a supervised exercise program during chemotherapy. The exercise group will engage in two 60-minute sessions weekly of high-intensity interval and strength training, supported by a personalized mobile app and local physiotherapists. The program starts with a moderate warm-up and is tailored to each patients fitness and perceived exertion, continuing from the start of chemotherapy until surgery, about five months. Throughout the study, participants will be carefully monitored with questionnaires, physical tests, and device-based activity tracking. Assessments include quality of life surveys, physical activity reports, muscle strength tests, cognitive function scans, fitness evaluations, tumor imaging, chemotherapy completion rates, and sick leave data. The primary outcome, pathological complete response, is assessed around 5-6 months after starting chemotherapy. Follow-up and data collection continue for up to two years to evaluate long-term effects and safety.
1-10 of 20
1